After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

The cornea is the clear, outermost layer of the eye. Its outer border, the limbus, contains a large volume of healthy stem ...

The Leukemia & Lymphoma Society (LLS) has launched a new docuseries to inform blood cancer patients, caregivers, healthcare ...

Leading epigenome company Tune Therapeutics is proud to announce that veteran drug-development executive John McHutchison AO, ...

Gilead Sciences sets aside $200 million for a potential settlement over its HIV drug promotional speaker program amid federal ...

About Arcellx and Kite Collaboration Arcellx and Kite, a Gilead Company, formed a global strategic collaboration and license agreement to co-develop and co-commercialize anito-cel for patients with ...

Gilead Sciences has bolstered its position in the development of next-generation cancer cell therapies with a deal to absorb Tmunity Therapeutics into its Kite unit. Kite has agreed to acquire all ...

COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts Data were from a retrospective chart review of patients with ...

Foster City: Gilead Sciences, Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir-the company’s twice-yearly ...